
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8585056/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission. Bone Marrow Transplantation, 2022, 57, 95-105.	2.4	8
2	Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience. Annals of Hematology, 2022, 101, 349-358.	1.8	12
3	NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan. International Journal of Hematology, 2022, , 1.	1.6	3
4	Outcomes of Different Haploidentical Transplantation Strategies from the Taiwan Blood and Marrow Transplantation Registry. Cancers, 2022, 14, 1097.	3.7	4
5	Stem cell transplant for mantle cell lymphoma in Taiwan. Scientific Reports, 2022, 12, 5662.	3.3	3
6	Orbital and ocular adnexal lymphoma: a review of epidemiology and prognostic factors in Taiwan. Eye, 2021, 35, 1946-1953.	2.1	12
7	RBC-derived vesicles as a systemic delivery system of doxorubicin for lysosomal-mitochondrial axis-improved cancer therapy. Journal of Advanced Research, 2021, 30, 185-196.	9.5	20
8	Comparison of clinicopathological features and treatment outcomes in aggressive primary intestinal B- and T/NK-cell lymphomas. Journal of the Formosan Medical Association, 2021, 120, 293-302.	1.7	4
9	Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome. Journal of the Formosan Medical Association, 2021, 120, 2144-2152.	1.7	9
10	CD9 Upregulation-Decreased CCL21 Secretion in Mesenchymal Stem Cells Reduces Cancer Cell Migration. International Journal of Molecular Sciences, 2021, 22, 1738.	4.1	6
11	Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. Journal of Hematology and Oncology, 2021, 14, 25.	17.0	41
12	Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Advances, 2021, 5, 2456-2466.	5.2	31
13	Busulfanâ€containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study. Cancer Reports, 2021, , e1488.	1.4	2
14	Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients. Journal of the Formosan Medical Association, 2021, 121, 643-643.	1.7	1
15	Validation of a <scp>Post-Transplant</scp> Lymphoproliferative Disorder Risk Prediction Score and Derivation of a New Prediction Score Using a National Bone Marrow Transplant Registry Database. Oncologist, 2021, 26, e2034-e2041.	3.7	5
16	A Clinicopathological Study of Cytomegalovirus Lymphadenitis and Tonsillitis and Their Association with Epstein–Barr Virus. Infectious Diseases and Therapy, 2021, 10, 2661-2675.	4.0	4
17	ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden. Blood Cancer Journal, 2020, 10, 99.	6.2	5
18	Correlative analysis of overall survival with clinical characteristics in 127 patients with mantle cell lymphoma: a multi-institutional cohort in Taiwan. International Journal of Hematology, 2020, 112, 385-394.	1.6	2

#	Article	IF	CITATIONS
19	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Annals of Hematology, 2020, 99, 501-511.	1.8	52
20	Next-Generation Sequencing Minimal Residual Disease of Mantle Cell Lymphoma in Autologous Stem Cell Grafts and Its Implication on Tumor Recurrence. Blood, 2020, 136, 22-23.	1.4	0
21	Low-dose splenic irradiation is an alternative therapy for symptomatic splenomegaly in patients with myelofibrosis. Annals of Hematology, 2019, 98, 1037-1040.	1.8	1
22	Autologous stem cell transplantation in multiple myeloma: Post-transplant outcomes of Taiwan Blood and Marrow Transplantation Registry. Journal of the Formosan Medical Association, 2019, 118, 471-480.	1.7	3
23	Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients. EBioMedicine, 2019, 40, 240-250.	6.1	23
24	The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan. Annals of Hematology, 2019, 98, 745-752.	1.8	12
25	Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2019, 19, 617.	2.6	43
26	Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. British Journal of Haematology, 2019, 186, 72-85.	2.5	11
27	Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study. Blood, 2019, 134, 1568-1568.	1.4	11
28	The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia. Blood, 2019, 134, 2705-2705.	1.4	0
29	Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2018, 101, 28-37.	2.2	8
30	Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome. Blood Cancer Journal, 2018, 8, 39.	6.2	68
31	Hyperleukocytosis is associated with distinct genetic alterations and is an independent poorâ€risk factor in <i>de novo</i> acute myeloid leukemia patients. European Journal of Haematology, 2018, 101, 86-94.	2.2	31
32	Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation. Clinical and Experimental Ophthalmology, 2018, 46, 698-700.	2.6	14
33	Dextran-coated iron oxide nanoparticle-improved therapeutic effects of human mesenchymal stem cells in a mouse model of Parkinson's disease. Nanoscale, 2018, 10, 2998-3007.	5.6	53
34	Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clinical Epigenetics, 2018, 10, 42.	4.1	36
35	Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. Journal of Hepatology, 2018, 69, 286-292.	3.7	76
36	2016 guideline strategies for the use ofÂantifungal agents in patients with hematological malignancies or hematopoietic stem cell transplantation recipients in Taiwan. Journal of Microbiology, Immunology and Infection, 2018, 51, 287-301.	3.1	13

#	Article	IF	CITATIONS
37	Airway Delivery of Bone Marrow–Derived Mesenchymal Stem Cells Reverses Bronchopulmonary Dysplasia Superimposed with Acute Respiratory Distress Syndrome in an Infant. Cell Medicine, 2018, 10, 215517901875943.	5.0	10
38	Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome. EBioMedicine, 2018, 37, 91-100.	6.1	54
39	GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. Blood Cancer Journal, 2018, 8, 87.	6.2	34
40	Concomitant <i>WT1</i> mutations predict poor prognosis in acute myeloid leukemia patients with double mutant <i>CEBPA</i> . Haematologica, 2018, 103, e510-e513.	3.5	29
41	Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 2310-2315.	2.0	4
42	Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan. BMC Gastroenterology, 2018, 18, 6.	2.0	20
43	Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008–2013. International Journal of Antimicrobial Agents, 2017, 49, 272-281.	2.5	41
44	Cervical Papanicolaou Smears in Hematopoietic Stem Cell Transplant Recipients: High Prevalence of Therapy-Related Atypia during the Acute Phase. Biology of Blood and Marrow Transplantation, 2017, 23, 1367-1373.	2.0	3
45	Adult T cell leukemia/lymphoma presenting as multiple necrotic ulcers. Dermatologica Sinica, 2017, 35, 157-158.	0.5	1
46	Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma. Journal of Radiation Research, 2017, 58, 114-122.	1.6	12
47	Prognostic impacts and dynamic changes of cohesin complex gene mutations in de novo acute myeloid leukemia. Blood Cancer Journal, 2017, 7, 663.	6.2	39
48	Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas. Oncotarget, 2017, 8, 81329-81342.	1.8	6
49	Complete response of myeloid sarcoma with cardiac involvement to radiotherapy. Journal of Thoracic Disease, 2016, 8, 1323-1328.	1.4	8
50	Dextran-coated iron oxide nanoparticles turn protumor mesenchymal stem cells (MSCs) into antitumor MSCs. RSC Advances, 2016, 6, 45553-45561.	3.6	12
51	Reduced incidence of interstitial pneumonitis after allogeneic hematopoietic stem cell transplantation using a modified technique of total body irradiation. Scientific Reports, 2016, 6, 36730.	3.3	18
52	Multiple Giant Mushroom-like Tumors Inside the Stomach. Gastroenterology, 2016, 151, e9-e10.	1.3	2
53	Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Oncotarget, 2016, 7, 63177-63188.	1.8	21
54	Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget, 2016, 7, 62490-62502.	1.8	30

#	Article	IF	CITATIONS
55	Splicing factor mutations predict poor prognosis in patients with <i>de novo</i> acute myeloid leukemia. Oncotarget, 2016, 7, 9084-9101.	1.8	77
56	Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome. Blood, 2016, 128, 49-49.	1.4	0
57	Clinical and Prognostic Implications of Roundabout 4 (Robo4) in Adult Patients with Acute Myeloid Leukemia. PLoS ONE, 2015, 10, e0119831.	2.5	6
58	High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS ONE, 2015, 10, e0126037.	2.5	21
59	Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study. PLoS ONE, 2015, 10, e0137552.	2.5	7
60	Clinical characteristics and treatment outcomes of patients with candidaemia due to <i>Candida parapsilosis sensu lato</i> species at a medical centre in Taiwan, 2000–12. Journal of Antimicrobial Chemotherapy, 2015, 70, 1531-1538.	3.0	21
61	GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution. Annals of Hematology, 2015, 94, 211-221.	1.8	23
62	High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. PLoS ONE, 2015, 10, e0128410.	2.5	50
63	Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer, 2015, 15, 344.	2.6	48
64	Ferucarbotran, a carboxydextran-coated superparamagnetic iron oxide nanoparticle, induces endosomal recycling, contributing to cellular and exosomal EGFR overexpression for cancer therapy. RSC Advances, 2015, 5, 89932-89939.	3.6	11
65	Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia. Blood, 2015, 126, 4956-4956.	1.4	0
66	Demographics and Long-Term Outcome of Incident Immune Thrombocytopenic Purpura: A Twelve-Years Nationwide Population-Based Study in Taiwan. Blood, 2015, 126, 3259-3259.	1.4	1
67	IPSSâ€R in 555 <scp>Taiwanese</scp> patients with primary MDS: Integration of monosomal karyotype can better riskâ€stratify the patients. American Journal of Hematology, 2014, 89, E142-9.	4.1	16
68	<i>IDH</i> mutations are closely associated with mutations of <i>DNMT3A</i> , <i>ASXL1</i> and <i>SRSF2</i> in patients with myelodysplastic syndromes and are stable during disease evolution. American Journal of Hematology, 2014, 89, 137-144.	4.1	76
69	Clinical implications of the <i>SETBP1</i> mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 2014, 89, 181-186.	4.1	56
70	Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology, 2014, 59, 2092-2100.	7.3	235
71	Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Annals of Hematology, 2014, 93, 1371-1380.	1.8	54
72	Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. Leukemia Research, 2014, 38, 1278-1284.	0.8	22

#	Article	IF	CITATIONS
73	<i>SF3B1</i> mutations in patients with myelodysplastic syndromes: The mutation is stable during disease evolution. American Journal of Hematology, 2014, 89, E109-15.	4.1	34
74	The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression. Haematologica, 2014, 99, 1799-1807.	3.5	13
75	Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis. BMC Cancer, 2013, 13, 107.	2.6	11
76	Crystal-storing histiocytosis in a patient with ocular extranodal marginal zone lymphoma. British Journal of Haematology, 2013, 160, 419-419.	2.5	8
77	Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence—clinical implication and comparison between the West and the East. Annals of Hematology, 2013, 92, 799-806.	1.8	14
78	Clinical features of patients with infections caused by Candida guilliermondii and Candida fermentati and antifungal susceptibility of the isolates at a medical centre in Taiwan, 2001-10. Journal of Antimicrobial Chemotherapy, 2013, 68, 2632-2635.	3.0	24
79	Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression. American Journal of Hematology, 2013, 88, E277-82.	4.1	56
80	Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood, 2013, 121, 3172-3180.	1.4	58
81	Clinical and Microbiological Characteristics of Perianal Infections in Adult Patients with Acute Leukemia. PLoS ONE, 2013, 8, e60624.	2.5	48
82	The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood, 2012, 120, 3106-3111.	1.4	127
83	Intracranial hemorrhage in adult patients with hematological malignancies. BMC Medicine, 2012, 10, 97.	5.5	58
84	Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001–2010. International Journal of Antimicrobial Agents, 2012, 40, 533-538.	2.5	30
85	Relapse of Acute Myeloid Leukemia at the Pituitary Gland: A Case Report and Review of Literature. Endocrine Pathology, 2012, 23, 172-176.	9.0	6
86	DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood, 2012, 119, 559-568.	1.4	211
87	Simultaneous determination of triazole antifungal drugs in human plasma by sweeping-micellar electrokinetic chromatography. Analytical and Bioanalytical Chemistry, 2012, 404, 217-228.	3.7	17
88	Iron Oxide Nanoparticle-Induced Epidermal Growth Factor Receptor Expression in Human Stem Cells for Tumor Therapy. ACS Nano, 2011, 5, 9807-9816.	14.6	43
89	Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review. Medical Mycology, 2011, 49, 1-7.	0.7	31
90	Soluble triggering receptor expressed on myeloid cells-1 as an infection marker for patients with neutropenic fever*. Critical Care Medicine, 2011, 39, 993-999.	0.9	6

#	Article	IF	CITATIONS
91	Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus–mediated B-cell proliferation. Blood, 2011, 118, 1340-1349.	1.4	21
92	TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood, 2011, 118, 3803-3810.	1.4	272
93	In vivo magnetic resonance imaging of cell tropsim, trafficking mechanism, and therapeutic impact of human mesenchymal stem cells in a murine glioma model. Biomaterials, 2011, 32, 3275-3284.	11.4	58
94	Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID. Blood, 2011, 118, 114-114.	1.4	2
95	Clinical Relevance of Pre- and Post-Transplantation Residual Disease, Hematogones and Natural Killer Cells in Adult Patients with Acute Leukemia. Blood, 2011, 118, 4490-4490.	1.4	Ο
96	Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia. Haematologica, 2010, 95, 1420-1424.	3.5	17
97	Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 2010, 115, 2749-2754.	1.4	193
98	WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood, 2010, 115, 5222-5231.	1.4	156
99	The inhibitory effect of superparamagnetic iron oxide nanoparticle (Ferucarbotran) on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells. Toxicology and Applied Pharmacology, 2010, 245, 272-279.	2.8	147
100	Papillary Thyroid Cancer Associated With Light-Chain Amyloidosis Initially Presenting With Small-Bowel Bleeding and Protein-Losing Enteropathy. Journal of Clinical Oncology, 2010, 28, e557-e559.	1.6	3
101	Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood, 2010, 116, 4086-4094.	1.4	187
102	Homologous RBC-derived vesicles as ultrasmall carriers of iron oxide for magnetic resonance imaging of stem cells. Nanotechnology, 2010, 21, 235103.	2.6	32
103	The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. Biomaterials, 2009, 30, 3645-3651.	11.4	305
104	Granulomatous Slack Skin Presenting as Acquired Ichthyosis and Muscle Masses. American Journal of Clinical Dermatology, 2009, 10, 29-32.	6.7	5
105	HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia. Journal of the Formosan Medical Association, 2009, 108, 423-427.	1.7	2
106	Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood, 2009, 113, 3161-3167.	1.4	75
107	AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood, 2009, 114, 5352-5361.	1.4	318
108	AML1/RUNX1 Mutations in 470 Adult Patients with De Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations Blood, 2009, 114, 1564-1564.	1.4	3

#	Article	IF	CITATIONS
109	Role of Gene Mutations in Adult Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2009, 114, 3373-3373.	1.4	0
110	Mesoporous Silica Nanoparticles Improve Magnetic Labeling Efficiency in Human Stem Cells. Small, 2008, 4, 619-626.	10.0	128
111	Mesoporous Silica Nanoparticles as a Delivery System of Gadolinium for Effective Human Stem Cell Tracking. Small, 2008, 4, 1445-1452.	10.0	201
112	Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leukemia Research, 2008, 32, 904-912.	0.8	55
113	Internalization of mesoporous silica nanoparticles induces transient but not sufficient osteogenic signals in human mesenchymal stem cells. Toxicology and Applied Pharmacology, 2008, 231, 208-215.	2.8	122
114	Clinical Characteristics and Treatment Response of Hodgkin's Lymphoma in Taiwan. Journal of the Formosan Medical Association, 2008, 107, 4-12.	1.7	6
115	Lung Abscess due to <i>Clostridium baratii</i> Infection in a Patient with Invasive Pulmonary Aspergillosis. Journal of Clinical Microbiology, 2008, 46, 1153-1154.	3.9	3
116	Pleural Effusion Heralds Acute Leukemic Transformation of Chronic Myelomonocytic Leukemia. Southern Medical Journal, 2008, 101, 1279-1280.	0.7	6
117	Clinical and Biological Characterization of Adult Patients with Acute Myeloid Leukemia Bearing T(7;11)(p15;p15)—Analysis of 536 Patients. Blood, 2008, 112, 2535-2535.	1.4	1
118	Acquisition and Cure of Autoimmune Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Journal of the Formosan Medical Association, 2007, 106, 779-783.	1.7	3
119	Anaplastic Large Cell Lymphoma in Leukemic Transformation: Successful Treatment by Transplantation. Journal of Clinical Oncology, 2007, 25, 4490-4492.	1.6	2
120	Bifunctional Magnetic Silica Nanoparticles for Highly Efficient Human Stem Cell Labeling. Nano Letters, 2007, 7, 149-154.	9.1	486
121	Epidemiology of multiple myeloma in Taiwan. Cancer, 2007, 110, 896-905.	4.1	92
122	The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials, 2007, 28, 2959-2966.	11.4	561
123	<i>RUNX1</i> gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. British Journal of Haematology, 2007, 139, 405-414.	2.5	122
124	MR Findings of Intrathecal Chemotherapyâ€Related Myelopathy in Two Cases: Mimicker of Subacute Combined Degeneration. Journal of Neuroimaging, 2007, 17, 184-187.	2.0	21
125	Gene Mutations, Their Interactions and Associations with Immunophenotypes of Leukemia Cells in Patients with Primary Acute Myeloid Leukemia Blood, 2007, 110, 4138-4138.	1.4	0
126	Diffuse depigmentation in a patient with chronic myeloid leukemia. Journal of the American Academy of Dermatology, 2006, 54, 738-740.	1.2	4

#	Article	IF	CITATIONS
127	Clinical implications of SOCS1 methylation in myelodysplastic syndrome. British Journal of Haematology, 2006, 135, 317-323.	2.5	32
128	<i>Nucleophosmin</i> Mutations in <i>De novo</i> Acute Myeloid Leukemia: The Age-Dependent Incidences and the Stability during Disease Evolution. Cancer Research, 2006, 66, 3310-3316.	0.9	165
129	Quantitative Assessment of Minimal Residual Disease Predicts Outcome of Patients of Acute Myeloid Leukemia with Nucleophosmin (NPM) Mutation Blood, 2006, 108, 561-561.	1.4	6
130	Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells. Clinical Cancer Research, 2005, 11, 1372-1379.	7.0	202
131	Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer, 2004, 100, 366-375.	4.1	185
132	Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. Journal of the Formosan Medical Association, 2004, 103, 526-32.	1.7	34
133	Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Annals of Hematology, 2003, 82, 558-564.	1.8	15
134	SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes and Cancer, 2003, 37, 300-305.	2.8	108
135	Incidence and predictors of idiopathic pneumonia syndrome in hematopoietic stem cell transplant patients: a nationwide registry study. International Journal of Hematology, 0, , .	1.6	1